Delving into the Latest Updates on Typhoid and Paratyphoid A conjugate without adjuvant vaccine(GlaxoSmithKline) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Conjugated vaccine

Synonyms

TYP04

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication-

Inactive Indication

Typhoid Fever

Originator Organization

GSK Plc

Active Organization-

Inactive Organization

GSK Plc

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

A bivalent Typhoid and Paratyphoid A conjugate investigational vaccine aimed to prevent both typhoid and paratyphoid enteric fever in infants and older age groups has been developed by GlaxoSmithKline (GSK).
The purpose of this first-time-in-human study is to evaluate the safety and immunogenicity profile of a low and a full dose of the investigational vaccine, formulated with or without adjuvant, administered in 2 doses, 24 weeks apart, in healthy adults 18 to 50 years of age in Europe.

Start Date28 Nov 2022

Sponsor / Collaborator

GSK Plc

[+1]

100 Clinical Results associated with Typhoid and Paratyphoid A conjugate without adjuvant vaccine(GlaxoSmithKline)

Login to view more data

100 Translational Medicine associated with Typhoid and Paratyphoid A conjugate without adjuvant vaccine(GlaxoSmithKline)

Login to view more data

100 Patents (Medical) associated with Typhoid and Paratyphoid A conjugate without adjuvant vaccine(GlaxoSmithKline)

Login to view more data

100 Deals associated with Typhoid and Paratyphoid A conjugate without adjuvant vaccine(GlaxoSmithKline)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Typhoid Fever	Phase 1	Belgium	GSK Plc	28 Nov 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05613205 (CTgov)	Phase 1	Typhoid Fever	97	Alum (Step 1a: Low Dose TYP04A Vaccine Without Alum)	kjavtceevs = ccwssovgdy ivyguxhkdj (wrsvwmaeio, tzhjkmwnke - tlfnyjrhjp) View more	-	24 Jan 2025
				TYP03A+Alum investigational vaccine (Step 1b: Low Dose TYP03A Vaccine With Alum)	kjavtceevs = yypvijelsu ivyguxhkdj (wrsvwmaeio, wvqgzemyze - laouslpkvq) View more